ICU stock icon

SeaStar Medical

2.54 USD
+0.17
7.17%
At close Dec 4, 4:00 PM EST
Pre-market
2.59
+0.05
1.97%
1 day
7.17%
5 days
1.60%
1 month
-9.93%
3 months
-51.62%
6 months
-71.36%
Year to date
-78.10%
1 year
-80.23%
5 years
-99.07%
10 years
-99.07%
 

About: SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

Employees: 12

0
Funds holding %
of 6,790 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

2.69% less ownership

Funds ownership: 5.95% [Q2] → 3.26% (-2.69%) [Q3]

12% less funds holding

Funds holding: 17 [Q2] → 15 (-2) [Q3]

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

53% less capital invested

Capital invested by funds: $1.25M [Q2] → $584K (-$668K) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for ICU.

Financial journalist opinion

Based on 5 articles about ICU published over the past 30 days

Neutral
GlobeNewsWire
1 day ago
SeaStar Medical to Hold Business Update Conference Call on December 11, 2024
DENVER, Dec. 04, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will hold a conference call to discuss business progress and updates.
SeaStar Medical to Hold Business Update Conference Call on December 11, 2024
Neutral
GlobeNewsWire
1 week ago
SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024
DENVER, Nov. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present a company overview at NobleCon20, Noble Capital Markets' 20th Annual Emerging Growth Equity Conference, on Wednesday, December 4 at 12:00 p.m. Eastern time (9:00 a.m. Pacific time). The conference is being held in Boca Raton, Fla.
SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024
Neutral
GlobeNewsWire
1 week ago
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical's Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares
SeaStar Medical urges stockholders to vote FOR all proxy proposals prior to the Special Meeting of Stockholders to be held November 26, 2024
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical's Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares
Neutral
GlobeNewsWire
2 weeks ago
SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer
DENVER, Nov. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has begun shipping QUELIMMUNE™ to a third hospital customer. QUELIMMUNE is the Company's Selective Cytopheretic Device (SCD) for treating critically ill children in the intensive care unit (ICU) with acute kidney injury (AKI) and sepsis.
SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer
Neutral
GlobeNewsWire
3 weeks ago
SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update
DENVER, Nov. 13, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and nine months ended September 30, 2024, and provides a business update.
SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update
Neutral
GlobeNewsWire
1 month ago
Record Monthly Enrollment Achieved in SeaStar Medical's Pivotal Adult AKI Trial
DENVER, Nov. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports setting a new monthly enrollment record with 10 critically ill acute kidney injury (AKI) patients added to the NEUTRALIZE-AKI pivotal trial during the past month, bringing total enrollment to 56. This trial is evaluating the safety and efficacy of the Company's proprietary therapeutic Selective Cytopheretic Device (SCD) in adults with AKI in the intensive care unit (ICU) receiving continuous renal replacement therapy (CRRT).
Record Monthly Enrollment Achieved in SeaStar Medical's Pivotal Adult AKI Trial
Neutral
GlobeNewsWire
1 month ago
SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE
DENVER, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has shipped QUELIMMUNE™ directly to a second hospital customer. QUELIMMUNE is the Company's Selective Cytopheretic Device (SCD) for treating critically ill children in the intensive care unit (ICU) with acute kidney injury (AKI) and sepsis. QUELIMMUNE was granted U.S. Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption (HDE).
SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE
Neutral
GlobeNewsWire
1 month ago
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update
Data illustrate the potential of QUELIMMUNE ™️ with cost neutrality starting at 6 days of therapy and a significant reduction in total hospitalization costs in children with acute kidney injury
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update
Neutral
GlobeNewsWire
1 month ago
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024
Data illustrate the potential of QUELIMMUNE ™️ with cost neutrality starting at 6 days of therapy and a significant reduction in total hospitalization costs in children with acute kidney injury
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024
Neutral
GlobeNewsWire
1 month ago
SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers
DENVER, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that it has assumed all responsibility for direct sales, marketing and distribution of QUELIMMUNE™ to hospital customers. QUELIMMUNE is SeaStar Medical's therapeutic device approved for the treatment of pediatric acute kidney injury (AKI) due to sepsis or a septic-like condition.
SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers
Charts implemented using Lightweight Charts™